ストックスクリーナーアプリを入手
8.28
3.38%
-0.29
アフターアワーズ：
8.28
前日終値:
$8.57
開ける：
$8.47
24時間の取引高:
1.14M
Relative Volume:
4.42
時価総額：
$370.85M
収益：
$84.82M
当期純損益:
$-21.43M
株価収益率:
-9.3034
EPS:
-0.89
ネットキャッシュフロー:
$-27.23M
1週間 パフォーマンス:
-12.20%
1か月 パフォーマンス:
-21.44%
6か月 パフォーマンス:
-29.53%
1年 パフォーマンス:
+35.74%
1日の値動き範囲:
$7.996
$8.50
1週間の範囲:
$7.996
$11.10
52週間の値動き範囲:
$6.10
$20.90
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
YMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
8.28 | 370.85M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-18 | 開始されました | Oppenheimer | Outperform |
| 2024-08-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-28 | 開始されました | Truist | Buy |
| 2023-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-04-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-01-27 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-12-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-10-31 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-10-31 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 再開されました | Guggenheim | Buy |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-11-16 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-04-23 | 再開されました | Cowen | Outperform |
| 2021-03-22 | 再開されました | JP Morgan | Overweight |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2020-05-01 | 開始されました | Janney | Buy |
| 2020-04-29 | 開始されました | Morgan Stanley | Equal-Weight |
| 2019-12-24 | 開始されました | JP Morgan | Overweight |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-09-04 | 開始されました | Wedbush | Outperform |
| 2019-04-01 | 開始されました | H.C. Wainwright | Buy |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-10-16 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Y Mabs Therapeutics Inc (YMAB) 最新ニュース
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely - Yahoo Finance
(YMAB) Trading Signals - Stock Traders Daily
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Australia
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Buy” by Brokerages - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Buy” Rating from HC Wainwright - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Receives "Buy" Rating from HC Wainwright - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Equities Analysts Offer Predictions for YMAB FY2024 Earnings - MarketBeat
Brookline Capital Management Predicts YMAB FY2024 Earnings - Defense World
Intech Investment Management LLC Invests $133,000 in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Trend Tracker for (YMAB) - Stock Traders Daily
Y-mAbs' CD38-SADA Shows Promising Anti-Tumor Results in NHL Treatment at ASH Meeting - StockTitan
United Rentals (URI-N) QuotePress Release - The Globe and Mail
Brookline Capital Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Buy Recommendation - MSN
Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Increased to Strong-Buy at Brookline Capital Management - MarketBeat
Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics - Inkl
Pork Cutout (KMV25) Quote - The Globe and Mail
Nasdaq-100 Ex-Tech Sector Index (NDXX) QuotePress Release - The Globe and Mail
TSX 60 ESG Index (TSXE) QuotePress Release - The Globe and Mail
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
Corn Falling to Start Midweek Trade - The Globe and Mail
Robusta Coffee 10-T (RMK21) Quote - The Globe and Mail
Amer Superconductor (AMSC-Q) QuotePress Release - The Globe and Mail
Caligan Partners LP Has $15.72 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference - The Manila Times
Y-mAbs Therapeutics to Present at Citi's 2024 Global Healthcare Conference | YMAB Stock News - StockTitan
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Principal Financial Group Inc. Makes New Investment in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Royal Bank of Canada (RY-T) QuotePress Release - The Globe and Mail
S&P 500 Energy [Sector] (SREN) QuotePress Release - The Globe and Mail
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Robusta Coffee 10-T (RMU21) Quote - The Globe and Mail
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript - MSN
Oppenheimer Begins Coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapies - MSN
Oppenheimer Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Outperform Recommendation - MSN
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26% - Simply Wall St
Brain Cancer Treatment Market Growth Overview Future - openPR
Y-mAbs Therapeutics (NASDAQ:YMAB) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock - Benzinga
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Receives Buy Rating from HC Wainwright - MarketBeat
Trading (YMAB) With Integrated Risk Controls - Stock Traders Daily
MSCI EMI Index (DEZ20) Quote - The Globe and Mail
YMAB FY2024 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate - Scrip
Cantor Fitzgerald Issues Positive Outlook for YMAB Earnings - MarketBeat
Y Mabs Therapeutics Inc (YMAB) 財務データ
収益
当期純利益
現金流量
EPS
Y Mabs Therapeutics Inc (YMAB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Gad Thomas | CHIEF BUSINESS OFFICER |
Sep 13 '24 |
Sale |
13.47 |
65,000 |
875,550 |
97,681 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Sep 16 '24 |
Sale |
12.97 |
30,000 |
389,100 |
67,681 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):